Details for Patent: 11,273,160
✉ Email this page to a colleague
Which drugs does patent 11,273,160 protect, and when does it expire?
Patent 11,273,160 protects GAVRETO and is included in one NDA.
This patent has twenty-seven patent family members in twenty-one countries.
Summary for Patent: 11,273,160
| Title: | RET inhibitor for use in treating cancer having a RET alteration |
| Abstract: | Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily. |
| Inventor(s): | Evans Raab; Erica (Cambridge, MA), Wolf; Beni B. (Cambridge, MA) |
| Assignee: | BLUEPRINT MEDICINES CORPORATION (Cambridge, MA) |
| Application Number: | 17/127,041 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 11,273,160
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines | GAVRETO | pralsetinib | CAPSULE;ORAL | 213721-001 | Sep 4, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ADULT PATIENTS WITH METASTATIC REARRANGED DURING TRANSFECTION (RET) FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,273,160
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019247766 | ⤷ Try a Trial | |||
| Brazil | 112020020273 | ⤷ Try a Trial | |||
| Canada | 3096043 | ⤷ Try a Trial | |||
| Chile | 2020002544 | ⤷ Try a Trial | |||
| China | 110891573 | ⤷ Try a Trial | |||
| Costa Rica | 20200522 | ⤷ Try a Trial | |||
| Denmark | 3773589 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
